Tysabri and PML: How Clinicians Distinguish Symptoms from Diagnosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Targeted Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, distinguishing early PML from other conditions is critical. This distinction builds on decades of pharmacovigilance research that has refined how clinicians assess risk and confirm diagnosis through imaging and lab tests. Here, we clarify the clinical context for symptoms versus diagnosis in Tysabri-associated PML.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's strongest safety alert, specifically addressing this risk. The clinical presentation of PML is variable but often includes progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual changes, and speech difficulties. Diagnosis is confirmed through brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Because PML can mimic multiple sclerosis relapses, clinicians must maintain a high index of suspicion, especially in patients receiving Tysabri.

Pharmacological Mechanism and Risk Factors

The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs normal immune surveillance against JC virus. Under these conditions, latent JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are seronegative. The risk also increases with cumulative exposure, and patients who have previously taken immunosuppressants such as mitoxantrone, cyclophosphamide, or azathioprine are at elevated risk.

Regulatory Warnings and Adverse Event Reports

The FDA Adverse Event Reporting System (FAERS) database contains thousands of reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they illustrate the range of neurological symptoms that may be reported by patients and that could overlap with early PML manifestations. The adequacy of warnings regarding Tysabri and PML has been a subject of regulatory and legal scrutiny. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information also instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse the drug.

Legal Considerations for PML Settlements

Despite these warnings, some patients have developed PML after receiving Tysabri, leading to legal claims for compensation. Settlement-related considerations for affected patients typically involve the timeline between exposure and documented harm. PML can occur after a few months to several years of Tysabri treatment, and the duration of therapy prior to onset is a critical factor in assessing risk and liability. Patients who develop PML may face substantial medical costs, long-term disability, and loss of quality of life. Legal claims often focus on whether the warnings provided to patients and healthcare providers were adequate to allow informed decision-making about the risks of treatment. In summary, the evidence clearly establishes that Tysabri increases the risk of PML, a devastating brain infection. The FDA has mandated strong warnings and a restricted distribution program to mitigate this risk. However, PML continues to occur in treated patients, and those affected may pursue legal remedies. The presence of anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use are key factors that elevate risk. Patients and clinicians must remain vigilant for early signs of PML, and any suspected case warrants immediate discontinuation of Tysabri and diagnostic evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. Tysabri works by blocking immune cell migration into the brain, which can allow latent JC virus to reactivate and cause PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors increase PML risk: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML from Tysabri?

Yes, patients who developed PML after Tysabri treatment may pursue legal claims for compensation. Legal claims often focus on whether the warnings provided were adequate. It is important to consult with an experienced attorney to evaluate your case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.